LT2782598T - Recombinant proteins and their therapeutic uses - Google Patents
Recombinant proteins and their therapeutic usesInfo
- Publication number
- LT2782598T LT2782598T LTEP12824705.3T LT12824705T LT2782598T LT 2782598 T LT2782598 T LT 2782598T LT 12824705 T LT12824705 T LT 12824705T LT 2782598 T LT2782598 T LT 2782598T
- Authority
- LT
- Lithuania
- Prior art keywords
- recombinant proteins
- therapeutic uses
- therapeutic
- recombinant
- proteins
- Prior art date
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563128P | 2011-11-23 | 2011-11-23 | |
| US201261654401P | 2012-06-01 | 2012-06-01 | |
| PCT/IB2012/002876 WO2013076580A2 (en) | 2011-11-23 | 2012-11-21 | Recombinant proteins and their therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2782598T true LT2782598T (en) | 2020-07-27 |
Family
ID=47716105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP12824705.3T LT2782598T (en) | 2011-11-23 | 2012-11-21 | Recombinant proteins and their therapeutic uses |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9902760B2 (en) |
| EP (2) | EP2782598B1 (en) |
| JP (4) | JP6121436B2 (en) |
| KR (2) | KR102274211B1 (en) |
| CN (3) | CN108864261A (en) |
| AU (3) | AU2012342117B2 (en) |
| BR (1) | BR112014012460B1 (en) |
| CA (1) | CA2856255C (en) |
| DK (1) | DK2782598T3 (en) |
| ES (1) | ES2812564T3 (en) |
| HR (1) | HRP20201282T1 (en) |
| HU (1) | HUE050438T2 (en) |
| IL (2) | IL232645B (en) |
| LT (1) | LT2782598T (en) |
| MX (1) | MX354902B (en) |
| MY (2) | MY188083A (en) |
| PL (1) | PL2782598T3 (en) |
| PT (1) | PT2782598T (en) |
| RS (1) | RS60782B1 (en) |
| RU (2) | RU2650574C2 (en) |
| SI (1) | SI2782598T1 (en) |
| WO (1) | WO2013076580A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY188083A (en) * | 2011-11-23 | 2021-11-16 | In3Bio Ltd | Recombinant proteins and their therapeutic uses |
| US20190358320A1 (en) * | 2015-05-12 | 2019-11-28 | In3Bio Ltd. | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors |
| US20160333087A1 (en) * | 2015-05-12 | 2016-11-17 | Bioven 3 Limited | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors |
| RU2020106669A (en) * | 2017-07-18 | 2021-08-18 | Ин3Байо Лтд. | SYNTHETIC PROTEINS AND WAYS OF THEIR THERAPEUTIC APPLICATION |
| CN113214410A (en) * | 2017-11-04 | 2021-08-06 | 海南大学 | Recombinant plasmid for expressing corticotropin and insulin-like growth factor 1 fusion protein and construction method of recombinant bacterium |
| WO2019179361A1 (en) * | 2018-03-21 | 2019-09-26 | 傅惠芳 | Composition for improving sphincter insufficiency and pharmaceutical composition and user thereof |
| WO2020046982A1 (en) * | 2018-08-27 | 2020-03-05 | University Of Virginia Patent Foundation | Compositions and methods for preventing and treating virus infection |
| CA3144845A1 (en) * | 2019-06-25 | 2020-12-30 | In3Bio Ltd. | Stabilized chimeric synthetic proteins and therapeutic uses thereof |
| KR20220099990A (en) | 2019-11-07 | 2022-07-14 | 인3바이오 리미티드 | Methods and compositions for using growth factor antibodies in combination with non-tyrosine-targeted kinase inhibitors |
| CN116003601A (en) * | 2019-12-05 | 2023-04-25 | 启愈生物技术(上海)有限公司 | anti-PD-L1 nano antibody and application thereof |
| US20230097992A1 (en) * | 2020-03-25 | 2023-03-30 | The Regents Of The University Of Colorado, A Body Corporate | Bivalent egf fusion toxins |
| CN113735980A (en) * | 2021-08-23 | 2021-12-03 | 中国医学科学院北京协和医院 | Self-fusion tandem protein modification method and application thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3238190A (en) | 1963-10-23 | 1966-03-01 | Madaus & Co K G Fa Dr | Aescin recovery |
| SE8205892D0 (en) | 1982-10-18 | 1982-10-18 | Bror Morein | IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| CA2137639C (en) * | 1993-12-09 | 1999-01-26 | Agustin B. L. Davila | Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases |
| CA2261433A1 (en) * | 1993-12-09 | 1995-06-10 | Belinda Sanchez Ramirez | Composition comprising autologous epidermal growth factor |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
| JPH10147952A (en) | 1996-11-18 | 1998-06-02 | Komatsu Ltd | Dozing device for bulldozer |
| ATE435661T1 (en) | 1997-08-29 | 2009-07-15 | Antigenics Inc | COMPOSITIONS CONTAINING ADJUVANT QS-21 WITH POLYSORBATE OR CYCLODEXTRIN AS AID |
| BR9815289A (en) * | 1997-11-14 | 2001-12-26 | Euro Celtique Sa | Modified immunoglobulin, molecule, isolated nucleic acid, cell containing the same, recombinant non-human animal, pharmaceutical composition, vaccine composition, processes for identifying or measuring or detecting a cancer antigen, an antigen from an infectious disease agent, a ligand, and a receptor in a sample. to be tested, kits for detecting a cancer antigen, an infectious disease agent antigen, a cell receptor for an infectious disease agent, a ligand, and a cancer antigen, diagnostic processes or testing for the presence of or a predisposition for the development of a cancer by the increased presence of a cancer antigen, and for the presence of an infectious disease, treatment or prevention of a cancer by the presence of a cancer antigen, of an infectious disease typified by the presence of an antigen infectious disease agent, and a disease caused by an infectious disease agent that binds to a cell receptor, processes for modulating activity of a first member of a binding pair, process for producing a modified immunoglobulin, process for producing a modified immunoglobulin nucleic acid, and, isolated nucleic acid |
| US6492325B1 (en) * | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
| DK1187629T3 (en) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| US7078486B2 (en) * | 1999-12-10 | 2006-07-18 | Spectral Diagnostics, Inc. | Single-chain polypeptides comprising troponin I and troponin C |
| JP2004504272A (en) * | 2000-03-23 | 2004-02-12 | グリーンビル ホスピタル システム | Bifunctional cancer treatment |
| CU22999A1 (en) | 2001-12-04 | 2004-10-12 | Centro Inmunologia Molecular | METHOD OF TREATMENT OF CHRONIC MALIGNAL AND INFECTIOUS DISEASES |
| EP1390065A2 (en) * | 2001-05-14 | 2004-02-25 | Duotol Ab | Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit |
| KR20090125840A (en) * | 2001-06-13 | 2009-12-07 | 젠맵 에이/에스 | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| US6833441B2 (en) * | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| EP1450828B1 (en) | 2001-08-17 | 2015-04-01 | Roger Williams Hospital | In situ immunization |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| WO2003102187A1 (en) * | 2002-05-31 | 2003-12-11 | Scegen Pty Ltd | Self-coalescing or self-aggregating proteins derived from a membrane translocating sequence |
| AU2003900481A0 (en) * | 2003-02-05 | 2003-02-20 | Queensland University Of Technology | Synthetic modulators of cell migration and growth |
| US8207314B2 (en) * | 2003-05-16 | 2012-06-26 | Sanofi Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
| US7601341B2 (en) * | 2003-06-05 | 2009-10-13 | Research Development Foundation | Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis |
| JP4623625B2 (en) | 2003-07-24 | 2011-02-02 | 株式会社ＡＭＢｉＳ | Heterotype pentamer recombinant vaccine |
| US7320795B2 (en) * | 2003-07-30 | 2008-01-22 | Vaccine Research Institute Of San Diego | Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
| EP1856255A4 (en) * | 2005-02-11 | 2010-01-27 | Univ Southern California | Method of expressing proteins with disulfide bridges |
| FR2882654B1 (en) * | 2005-03-01 | 2007-04-27 | Servier Lab | USE OF DIOSMETIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF THROMBOTIC DISEASES |
| CN1686562A (en) * | 2005-03-31 | 2005-10-26 | 南京大学 | Composition of transiron protein and biological reducing agent and its preparation method |
| BRPI0707679A2 (en) * | 2006-02-01 | 2011-05-10 | Tjhe Johns Hopkins University | polypeptide conjugate - Nucleic acid for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| ES2348312T3 (en) * | 2006-04-13 | 2010-12-02 | Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. | HER-2 / NEU VACCINE BASED ON MULTIPLE PEPTIDES. |
| DK2374818T3 (en) | 2006-06-02 | 2013-01-21 | Regeneron Pharma | High affinity antibodies to human IL-6 receptor |
| US20080064039A1 (en) * | 2006-07-06 | 2008-03-13 | Pienkos Philip T | Dominant negative ligand drug discovery system |
| AU2007292221B2 (en) * | 2006-09-06 | 2013-08-29 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
| EP1921149A1 (en) | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
| CN1995064A (en) * | 2006-12-20 | 2007-07-11 | 李欣越 | Long-lasting recombinant human red blood cell growth factor fusion protein and method |
| EP2115002B1 (en) * | 2007-02-02 | 2014-08-20 | Baylor Research Institute | Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells |
| BRPI0807344A2 (en) * | 2007-02-02 | 2014-05-20 | Baylor Res Inst | MULTI-VARIABLE ANTIGENS COMPLEXED WITH HUMANIZED MONOCLONAL STEERING ANTIBODY |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| KR101224468B1 (en) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | Bispecific antibody having a novel form and use thereof |
| JP2011187653A (en) | 2010-03-08 | 2011-09-22 | Olympus Corp | Waterproof apparatus |
| JP6167040B2 (en) | 2010-11-05 | 2017-07-19 | ザイムワークス，インコーポレイテッド | Design of stable heterodimeric antibodies with mutations in the Fc domain |
| MY188083A (en) * | 2011-11-23 | 2021-11-16 | In3Bio Ltd | Recombinant proteins and their therapeutic uses |
-
2012
- 2012-11-21 MY MYPI2018000286A patent/MY188083A/en unknown
- 2012-11-21 EP EP12824705.3A patent/EP2782598B1/en active Active
- 2012-11-21 LT LTEP12824705.3T patent/LT2782598T/en unknown
- 2012-11-21 RS RS20200986A patent/RS60782B1/en unknown
- 2012-11-21 CA CA2856255A patent/CA2856255C/en active Active
- 2012-11-21 RU RU2014124923A patent/RU2650574C2/en active
- 2012-11-21 DK DK12824705.3T patent/DK2782598T3/en active
- 2012-11-21 AU AU2012342117A patent/AU2012342117B2/en active Active
- 2012-11-21 JP JP2014542952A patent/JP6121436B2/en active Active
- 2012-11-21 MX MX2014006232A patent/MX354902B/en active IP Right Grant
- 2012-11-21 PT PT128247053T patent/PT2782598T/en unknown
- 2012-11-21 KR KR1020197027075A patent/KR102274211B1/en active IP Right Grant
- 2012-11-21 HU HUE12824705A patent/HUE050438T2/en unknown
- 2012-11-21 BR BR112014012460-4A patent/BR112014012460B1/en active IP Right Grant
- 2012-11-21 US US13/813,844 patent/US9902760B2/en active Active
- 2012-11-21 CN CN201810569310.3A patent/CN108864261A/en active Pending
- 2012-11-21 CN CN201280067891.1A patent/CN104066447A/en active Pending
- 2012-11-21 SI SI201231830T patent/SI2782598T1/en unknown
- 2012-11-21 KR KR1020147016995A patent/KR102024066B1/en active IP Right Grant
- 2012-11-21 WO PCT/IB2012/002876 patent/WO2013076580A2/en active Application Filing
- 2012-11-21 PL PL12824705T patent/PL2782598T3/en unknown
- 2012-11-21 ES ES12824705T patent/ES2812564T3/en active Active
- 2012-11-21 EP EP20170470.7A patent/EP3744343A1/en not_active Withdrawn
- 2012-11-21 MY MYPI2014701320A patent/MY184576A/en unknown
- 2012-11-21 CN CN201810569766.XA patent/CN108864291A/en active Pending
-
2014
- 2014-05-15 IL IL232645A patent/IL232645B/en active IP Right Grant
-
2016
- 2016-01-15 US US14/996,553 patent/US20160207972A1/en not_active Abandoned
-
2017
- 2017-03-29 JP JP2017064763A patent/JP6570081B2/en not_active Expired - Fee Related
- 2017-11-16 US US15/814,723 patent/US11198716B2/en active Active
- 2017-11-30 AU AU2017268634A patent/AU2017268634B2/en not_active Ceased
-
2018
- 2018-03-09 RU RU2018108421A patent/RU2766595C2/en active
-
2019
- 2019-04-04 JP JP2019072235A patent/JP6953467B2/en active Active
-
2020
- 2020-02-21 AU AU2020201297A patent/AU2020201297B2/en not_active Ceased
- 2020-08-14 HR HRP20201282TT patent/HRP20201282T1/en unknown
- 2020-12-22 IL IL279676A patent/IL279676A/en unknown
-
2021
- 2021-09-29 JP JP2021159307A patent/JP7470669B2/en active Active
- 2021-11-08 US US17/521,121 patent/US12030920B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279676A (en) | Recombinant proteins and their therapeutic uses | |
| IL260045B (en) | Polypeptide constructs and uses thereof | |
| HK1243427A1 (en) | Therapeutic peptides | |
| IL230918A0 (en) | Modified proteins and peptides | |
| HK1200489A1 (en) | Recombinant human naglu protein and uses thereof naglu | |
| HK1192587A1 (en) | Therapeutic fusion proteins | |
| EP2738255A4 (en) | Erap1-derived peptide and use thereof | |
| EP2711376A4 (en) | Fgfr-fc fusion protein and use thereof | |
| PL2668205T3 (en) | Human lactoferrin derived peptides and their use | |
| SG11201404180RA (en) | Cho-gmt recombinant protein expression | |
| EP2762149A4 (en) | Erythropoietin-derived peptide and use therefor | |
| EP2734543A4 (en) | Lactoferrin fragments and use thereof | |
| HK1211952A1 (en) | Recombinant protein | |
| GB201121226D0 (en) | Modified proteins and peptides | |
| GB201121233D0 (en) | Modified proteins and peptides | |
| GB201121236D0 (en) | Proteins and peptides | |
| IL230474B (en) | Lactoferrin fragments and use thereof |